China OKs study of Telix PET radiotracer for kidney cancer

By AuntMinnie.com staff writers

September 28, 2022 -- Telix Pharmaceuticals has received approval in China for a study of its investigational TLX250-CDx radiotracer for PET imaging of renal cancer.

The Chinese National Medical Products Administration Center for Drug Evaluation has approved a pivotal phase-III registration study that will bridge to Telix's phase-III study, Zirconium in Renal Cancer Oncology (ZIRCON) for TLX250-CDx.

TLX250-CDx is being developed as a PET imaging agent to characterize indeterminate renal masses previously identified on CT or MRI as clear cell renal cell cancer (ccRCC) or non-ccRCC.

This ZIRCON study aims to provide supplementary data obtained in a Chinese population with the hopes of establishing that the diagnostic efficacy of this investigational agent is equivalent in Chinese and Western populations. A dosimetry study enrolling 10 patients will precede the multicenter phase-III bridging study, which is expected to enroll 100 patients.


Copyright © 2022 AuntMinnie.com
 
Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: